Table 3. Summary of confirmed tumor response per RECIST V.1.1 by investigator assessment.
IO-108 monotherapyN=12 | IO-108+pembrolizumabN=13 | |
Efficacy evaluable, n | 11 | 12+1 crossover |
ORR (%) | 1 (9.1) | 3 (23.1) |
DCR (%) | 5 (45.5) | 7 (53.9) |
CR | 1 (9.1) | 0 (0) |
PR | 0 (0) | 3 (23.1) |
SD | 4 (36.4) | 4 (30.8) |
PD | 6 (54.5) | 6 (46.1) |
Not evaluable | 1 | 1 |
CRcomplete responseDCR, disease control rateORRobjective response ratePDdisease progressionPRpartial responseRECISTResponse Evaluation Criteria In Solid TumorsSDstable disease